Breaking News, Collaborations & Alliances

Matica Bio Partners with KaliVir

Will utilize its proprietary cell line, MatiMax, to explore a new manufacturing process for KaliVir’s oncolytic virus product.

Author Image

By: Charlie Sternberg

Associate Editor

Matica Biotechnology Inc., a CDMO specializing in viral vector development and manufacturing, has signed a Letter of Intent (LOI) with KaliVir Immunotherapeutics, a U.S.-based clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapies.   KaliVir is at the forefront of developing novel cancer therapies using its proprietary Vaccinia Enhanced Template (VET) platform, which allows for the expression and systemic delivery of multiple therapeutic...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters